Lisa Jarvis, Columnist

We Finally Have Some Paxlovid Covid Data. Now We Need More.

A study of health records for 60,000 patients suggests the treatment might be useful in preventing long Covid, but the conclusion is far from certain.

November 10, 2022 at 1:30 PM UTC

By Lisa Jarvis

Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News.

A five-day regimen in the early days of an infection lowered the risk of some symptoms in some patients. — A five-day regimen in the early days of an infection lowered the risk of some symptoms in some patients.
Photographer: Joe Raedle/Getty Images

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

A new study that mined health records from the Department of Veterans Affairs hints that the drug Paxlovid might be useful in preventing long Covid.

Scientists have been urging the government and the drug’s manufacturer, Pfizer, to study the idea that lingering virus could be the culprit behind some people’s long-term symptoms, and finally having data is a welcome advance.